Skip to main content
Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells

Fig. 8

Effects of GLPG1790 combined or not with irradiation on in vivo tumour growth. a Growth curve of tumour volumes from xenografted TE671 cell lines, untreated (vehicle), GLPG1790-treated (GLPG1790), irradiated (RT), GLPG1790-pretreated and irradiated (RT + GLPG1790). Tumour volumes were evaluated as describes in methods and represent the mean ± SEM of 10 mice. The upper panel shows the sequential treatments of xenografted mice started when tumours reached a volume of approximate 0.5 cm3. GLPG1790 (30 mg/kg) was administered 5 days a week for 2 weeks and before each irradiation, administered on alternate days. b Tumour weights in mice untreated or treated with GLPG1790, radiotherapy or combined treatment. c Kaplan-Meier estimates for rates of progression for untreated (vehicle), GLPG1790, RT, or GLPG1790 + RT combination in TE671-derived tumours. d Phosphorylation/activation status of EPH-A2, EPH-B, ERKs, AKTs and levels of Ki-67 protein in tumours from vehicle, RT, GLPG1790, or GLPG1790 + RT-treated mice (a, b). Representative Western blot experiment of the 10 tumours analysed. Total EPH-A2, EPH-B, ERKs, AKTs and α-Tubulin immunoblotting were used as loading control (lower panel)

Back to article page